TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tevogen Bio Holdings ( (TVGN) ) has shared an announcement.
On June 27, 2025, Tevogen Bio Holdings Inc. approved restricted stock award grants, including 8,000,000 shares to CEO Dr. Ryan Saadi, bringing the total outstanding shares to 193,693,433. The shares will vest over several years, with specific conditions for vesting and restrictions on transfer prior to vesting, impacting the company’s stock management and executive compensation strategy.
The most recent analyst rating on (TVGN) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Tevogen Bio Holdings stock, see the TVGN Stock Forecast page.
Spark’s Take on TVGN Stock
According to Spark, TipRanks’ AI Analyst, TVGN is a Underperform.
Tevogen Bio Holdings faces substantial financial risks due to consistent losses and high leverage, which are typical in its industry. Technical analysis indicates a bearish trend, and valuation metrics show speculative investment characteristics. However, the recent corporate event involving a strategic agreement provides a positive outlook for operational advancements, slightly balancing the financial and technical concerns.
To see Spark’s full report on TVGN stock, click here.
More about Tevogen Bio Holdings
Average Trading Volume: 970,319
Technical Sentiment Signal: Sell
Current Market Cap: $225M
For a thorough assessment of TVGN stock, go to TipRanks’ Stock Analysis page.